King's College London

Research portal

EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease

Research output: Contribution to journalArticle

Pablo Martinez-Martin, Prashanth Reddy, Regina Katzenschlager, Angelo Antonini, Antoniya Todorova, Per Odin, Tove Henriksen, Anne Martin, Daniela Calandrella, Alexandra Rizos, Narissah Bryndum, Arne Glad, Haidar Salimi Dafsari, Lars Timmermann, Georg Ebersbach, Milica G Kramberger, Michael Samuel, Karoline Wenzel, Volker Tomantschger, Alexander Storch & 7 others Heinz Reichmann, Zvezdan Pirtosek, Maja Trost, Per Svenningsson, Sven Palhagen, Jens Volkmann, K Ray Chaudhuri

Original languageEnglish
Pages (from-to)510-516
Number of pages7
JournalMovement disorders : official journal of the Movement Disorder Society
Volume30
Issue number4
DOIs
StatePublished - Apr 2015

King's Authors

Abstract

Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa infusion (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) and refractory motor complications, with varying cost of treatment. There are no multicenter studies comparing the effects of the two strategies. This open-label, prospective, observational, 6-month, multicenter study compared 43 patients on Apo (48.8% males, age 62.3 ± 10.6 years; disease duration: 14 ± 4.4 years; median H & Y stage 3; interquartile range [IQR]: 3-4) and 44 on IJLI (56.8% males, age 62.7 ± 9.1 years; disease duration: 16.1 ± 6.7 years; median H & Y stage 4; IQR, 3-4). Cohen's effect sizes (≥0.8 considered as large) were "large" with both therapies with respect to total motor, nonmotor, and quality-of-life scores. The Non-Motor Symptoms Scale (NMSS) with Apo showed moderate improvement, whereas sleep/fatigue, gastrointestinal, urinary, and sexual dimensions of the NMSS showed significantly higher improvement with IJLI. Seventy-five percent on IJLI improved in their quality-of-life and nonmotor symptoms (NMS), whereas in the Apo group, a similar proportion improved in quality of life, but 40% in NMS. Adverse effects included peritonitis with IJLI and skin nodules on Apo. Based on this open-label, nonrandomized, comparative study, we report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor symptoms, motor complications, quality-of-life, and some NMS. Controlled, randomized studies are required.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454